Study on the Therapeutic Effect of Rituximab in Patients with Membranous Nephropathy and Its Influence on T Lymphocyte Levels
Objective:To study the therapeutic effect of rituximab in patients with membranous nephropathy and its effect on T lym-phocyte levels.Methods:80 patients with membranous nephropathy treated in Fengcheng people's Hospital from January 2022 to April 2023 were selected and divided into two groups according to the random number table method.The control group was treated with cyclosporine and low-dose glucocorticoid,and the study group was treated with rituximab intravenous infusion.The clinical efficacy,T lymphocyte subsets(CD4+,CD8+,CD4+/CD8+),renal function[serum creatinine(SCR),24h urinary protein quantification,serum uric acid(BUA),albumin(ALB)]and adverse reactions were compared between the two groups.Results:compared with the control group,the total effective rate of the study group was higher;The levels of CD4+and CD4+/CD8+in the study group were lower,while the level of CD8+was higher;The SCR level,24h urinary protein quantification and BUA level in the study group were lower,while the alb level was higher,and the above differences were statistically significant(P＜0.05).There was no significant difference in adverse reactions between the two groups(P＞0.05).Conclusion:Rituximab is effective in the treatment of patients with membranous nephropathy,which can effectively improve the level of T lymphocyte subsets and renal function,and is relatively safe.
Membranous nephropathyRituximabCyclosporineGlucocorticoidsT LymphocytesRenal function
万方数据
维普
